



## **Janssen and Johnson & Johnson to Provide Webcast Presentation on Phase 3 Data for Apalutamide and the Janssen Prostate Cancer Strategy and Portfolio**

February 8, 2018

NEW BRUNSWICK, N.J., Feb. 8, 2018 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) and Johnson & Johnson (NYSE: JNJ) will provide a pre-recorded webcast focusing on the Phase 3 SPARTAN data for the investigational compound apalutamide in non-metastatic castration-resistant prostate cancer. The webcast is intended for investors and other interested parties, and will be available beginning at 5:00p.m EST on Thursday, February 8, 2018.

The pre-recorded webcast will feature Peter F. Lebowitz, MD, PhD, Global Therapeutic Area Head, Oncology, Janssen Research & Development, who will recap pivotal Phase 3 apalutamide data, which were featured at the American Society of Clinical Oncology Genitourinary (ASCO GU) 2018 Cancers Symposium. Dr. Lebowitz will also highlight the company's prostate cancer strategy and portfolio.

The webcast/podcast can be accessed by visiting the Johnson & Johnson website at [www.investor.jnj.com](http://www.investor.jnj.com) and clicking on "Webcasts/Presentations." The webcast duration is approximately 12 minutes and will be available through the end of April.



 View original content with multimedia: <http://www.prnewswire.com/news-releases/janssen-and-johnson--johnson-to-provide-webcast-presentation-on-phase-3-data-for-apalutamide-and-the-janssen-prostate-cancer-strategy-and-portfolio-300595750.html>

SOURCE Johnson & Johnson

News Provided by Acquire Media